Conv. Plasma
Nigella Sativa
Peg.. Lambda

All remdesivir studies
Meta analysis
Home COVID-19 treatment researchRemdesivirRemdesivir (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality, day 28 25% Improvement Relative Risk Mortality, day 14 30% Remdesivir  Mozaffari et al.  LATE TREATMENT Is late treatment with remdesivir beneficial for COVID-19? PSM retrospective 19,510 patients in the USA (Dec 2020 - Apr 2022) Lower mortality with remdesivir (p<0.000001) Mozaffari et al., Clinical Infectious .., Aug 2023 Favors remdesivir Favors control

Remdesivir reduced mortality in immunocompromised patients hospitalized for COVID-19 across variant waves: Findings from routine clinical practice.

Mozaffari et al., Clinical Infectious Diseases, doi:10.1093/cid/ciad460
Aug 2023  
  Source   PDF   All Studies   Meta AnalysisMeta
Retrospective 19,184 immunocompromised patients treated with remdesivir and matched controls, showing lower mortality with treatment. Several authors work at Gilead and the study was funded by Gilead.
The majority of patients were treated with remdesivir. A significant fraction of non-remdesivir patients may have contraindications that also increase risk. Authors provide serum creatine for 26% of the cohort, but notably provide only median and IQR, not allowing comparison of the number of patients with high values. Authors state that "renal function was not significantly different" between remdesivir and non-remdesivir patients, but this does not seem realistic given the prevalence of renal impairment and the contraindictions for remdesivir.
Gérard, Wu, Zhou show significantly increased risk of acute kidney injury with remdesivir.
risk of death, 25.0% lower, HR 0.75, p < 0.001, treatment 14,169, control 5,341, adjusted per study, propensity score matching, Cox proportional hazards, day 28.
risk of death, 30.0% lower, HR 0.70, p < 0.001, treatment 14,169, control 5,341, adjusted per study, propensity score matching, Cox proportional hazards, day 14.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Mozaffari et al., 9 Aug 2023, retrospective, USA, peer-reviewed, 11 authors, study period 1 December, 2020 - 30 April, 2022.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperRemdesivirAll
Remdesivir reduced mortality in immunocompromised patients hospitalized for COVID-19 across variant waves: Findings from routine clinical practice.
Essy Mozaffari, Aastha Chandak, Dr Robert L Gottlieb, Chidinma Chima-Melton, Stephanie H Read, Heng Jiang, Mel Chiang, Eunyoung Lee, Rikisha Gupta, Mark Berry, Dr Andre C Kalil
Clinical Infectious Diseases, doi:10.1093/cid/ciad460
Background: Immunocompromised patients are at high risk of severe COVID-19 and death, yet treatment strategies for immunocompromised patients hospitalized for COVID-19 reflect variations in clinical practice. This comparative effectiveness study investigated the effect of remdesivir treatment on inpatient mortality among immunocompromised patients hospitalized for COVID-19 across all variants of concern (VOC) periods.
Ao, The association between severe or death COVID-19 and solid organ transplantation: A systematic review and meta-analysis, Transplant Rev (Orlando)
Aydillo, Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer, N Engl J Med
Baek, COVID-19-related outcomes in immunocompromised patients: A nationwide study in Korea, PLOS ONE
Beigel, Remdesivir for the Treatment of Covid-19 -Final Report, New England Journal of Medicine
Beigel, Remdesivir for the Treatment of Covid-19 -Final Report, The New England journal of medicine
Bhimraj, Shumaker, Baden, Cheng, Edwards et al., Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19
Cacho, Use of remdesivir in kidney transplant recipients with SARS-CoV-2 Omicron infection, Kidney International
Chokkalingam, Association of Remdesivir Treatment With Mortality Among Hospitalized Adults With COVID-19 in the United States, JAMA Network Open
Crothers, Dexamethasone in hospitalised COVID-19 patients not on intensive respiratory support, Eur Respir J
Dougan, Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19
Ferdinands, Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study, BMJ
Focosi, Monoclonal antibody therapies against SARS-CoV-2, Lancet Infect Dis
Garibaldi, Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19, JAMA Network Open
Garibaldi, Real-World Effectiveness of Remdesivir in Adults Hospitalized With Coronavirus Disease 2019 (COVID-19): A Retrospective, Multicenter Comparative Effectiveness Study, Clinical Infectious Diseases
Gottlieb, Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients
Group, Dexamethasone in Hospitalized Patients with Covid-19
Jary, Spike Gene Evolution and Immune Escape Mutations in Patients with Mild or Moderate Forms of COVID-19 and Treated with Monoclonal Antibodies Therapies, Viruses
Jung, Steroid use in elderly critically ill COVID-19 patients, Eur Respir J
Koh, Real-world effectiveness of sotrovimab and remdesivir for early treatment of high-risk hospitalized COVID-19 patients: A propensity score adjusted retrospective cohort study, Journal of Medical Virology
Lambrou, Genomic Surveillance for SARS-CoV-2 Variants: Predominance of the Delta (B.1.617.2) and Omicron (B.1.1.529) Variants -United States, MMWR Morb Mortal Wkly Rep
Lee, Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis, BMJ
Les, Methylprednisolone Pulses in Hospitalized COVID-19 Patients Without Respiratory Failure: A Randomized Controlled Trial, Front Med (Lausanne)
Mackenna, Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform, Lancet Rheumatol
Mbaeyi, The Advisory Committee on Immunization Practices' Interim Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines -United States, 2021, MMWR Morb Mortal Wkly Rep
Mozaffari, Remdesivir treatment in hospitalized patients with COVID-19: a comparative analysis of in-hospital all-cause mortality in a large multi-center observational cohort, Clin Infect Dis
Pasin, Corticosteroids for Patients With Coronavirus Disease 2019 (COVID-19) With Different Disease Severity: A Meta-Analysis of Randomized Clinical Trials, J Cardiothorac Vasc Anesth
Paul, Genomic Surveillance for SARS-CoV-2 Variants Circulating in the United States, MMWR Morb Mortal Wkly Rep
Piccicacco, Real-world effectiveness of early remdesivir and sotrovimab in the highestrisk COVID-19 outpatients during the Omicron surge, Journal of Antimicrobial Chemotherapy
Planas, Considerable escape of SARS-CoV-2 Omicron to antibody neutralization, Nature
Rajme-López, Early Outpatient Treatment With Remdesivir in Patients at High Risk for Severe COVID-19: A Prospective Cohort Study, Open Forum Infectious Diseases
Shoham, Vaccines and therapeutics for immunocompromised patients with COVID-19. eClinicalMedicine
Singson, Factors Associated with Severe Outcomes Among Immunocompromised Adults Hospitalized for COVID-19 -COVID-NET, 10 States, MMWR Morb Mortal Wkly Rep
Song, Risk and Outcome of Breakthrough COVID-19 Infections in Vaccinated Patients With Cancer: Real-World Evidence From the National COVID Cohort Collaborative, J Clin Oncol
Spinner, Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial, JAMA
Sun, Association Between Immune Dysfunction and COVID-19 Breakthrough Infection After SARS-CoV-2 Vaccination in the US, JAMA Internal Medicine
Tartof, Analysis of mRNA COVID-19 Vaccine Uptake Among Immunocompromised Individuals in a Large US Health System, JAMA Network Open
Trøseid, Immunocompromised patients have been neglected in COVID-19 trials: a call for action, Clinical Microbiology and Infection
Turtle, Outcome of COVID-19 in hospitalised immunocompromised patients: An analysis of the WHO ISARIC CCP-UK prospective cohort study, PLOS Medicine
Van Doesum, Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post-CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey, Blood Adv
Vijenthira, Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients, Blood
Wilhelm, Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies. eBioMedicine
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop